Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

The host immunological response to cancer therapy: An emerging concept in tumor biology

Journal Article · · Experimental Cell Research
 [1];  [2];  [1]
  1. Department of Molecular Pharmacology, Rappaport Faculty of Medicine and the Rappaport Institute, Technion—Israel Institute of Technology, 1 Efron Street, Bat Galim, Haifa 31096 (Israel)
  2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht (Netherlands)

Almost any type of anti-cancer treatment including chemotherapy, radiation, surgery and targeted drugs can induce host molecular and cellular immunological effects which, in turn, can lead to tumor outgrowth and relapse despite an initial successful therapy outcome. Tumor relapse due to host immunological effects is attributed to angiogenesis, tumor cell dissemination from the primary tumors and seeding at metastatic sites. This short review will describe the types of host cells that participate in this process, the types of factors secreted from the host following therapy that can promote tumor re-growth, and the possible implications of this unique and yet only partially-known process. It is postulated that blocking these specific immunological effects in the reactive host in response to cancer therapy may aid in identifying new host-dependent targets for cancer, which in combination with conventional treatments can prolong therapy efficacy and extend survival. Additional studies investigating this specific research direction—both in preclinical models and in the clinical setting are essential in order to advance our understanding of how tumors relapse and evade therapy. -- Highlights: • Cancer therapy induces host molecular and cellular pro-tumorigenic effects. • Host effects in response to therapy may promote tumor relapse and metastasis. • The reactive host consists of immunological mediators promoting tumor re-growth. • Blocking therapy-induced host mediators may improve outcome.

OSTI ID:
22267815
Journal Information:
Experimental Cell Research, Journal Name: Experimental Cell Research Journal Issue: 11 Vol. 319; ISSN 0014-4827; ISSN ECREAL
Country of Publication:
United States
Language:
English

Similar Records

Cancer immunology
Book · Tue Dec 31 23:00:00 EST 1985 · OSTI ID:5190053

Combined Treatment Effects of Radiation and Immunotherapy: Studies in an Autochthonous Prostate Cancer Model
Journal Article · Thu Nov 14 23:00:00 EST 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22267948

Basic immunology of antibody targeted radiotherapy
Journal Article · Sun Oct 01 00:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20850087